# Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Martin Reck,Delvys Rodríguez‐Abreu,Andrew Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinéad Cuffe,Mary O’Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma Rangwala,Julie R. Brahmer |
| Citations | 10,184 |
| DOI | 10.1056/nejmoa1606774 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774?articleTools=true |
| OpenAlex ID | https://openalex.org/W2527905628 |
| PMID | 27718847 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.